Non-Small Cell Lung Carcinoma Advanced Locally TNM clinical staging | Non-small cell lung cancer metastatic TNM clinical staging | First line Chemotherapy
Item
histologically or cytologically confirmed locally advanced or metastatic (stage=iiib/iv) non-small cell lung cancer (nsclc) before the front line chemotherapy. note: sputum cytology alone is not acceptable
boolean
C0007131 (UMLS CUI [1,1])
C0205179 (UMLS CUI [1,2])
C1517927 (UMLS CUI [1,3])
C3258246 (UMLS CUI [1,4])
C0278987 (UMLS CUI [2,1])
C3258246 (UMLS CUI [2,2])
C1708063 (UMLS CUI [3,1])
C0392920 (UMLS CUI [3,2])
First line treatment Chemotherapy cycle Quantity | Chemotherapy Double Containing Platinum | Disease Progression Absent | Toxicity Absent
Item
patients have completed 4 cycles of first line platinum contained doublet chemotherapy without progression or intolerable toxicity.
boolean
C1708063 (UMLS CUI [1,1])
C1302181 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2,1])
C0205173 (UMLS CUI [2,2])
C0332256 (UMLS CUI [2,3])
C0032207 (UMLS CUI [2,4])
C0242656 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0600688 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
Partial response | Stable Disease | Measurable lesion Quantity
Item
patients with pr or sd on study entry need to have one or more measurable lesions according to recist criteria.
boolean
C1521726 (UMLS CUI [1])
C0677946 (UMLS CUI [2])
C1513041 (UMLS CUI [3,1])
C1265611 (UMLS CUI [3,2])
Clinical Trial Therapeutic procedure Start time | Chemotherapy | Tumor Assessment
Item
the study treatment should be started at least 3 weeks (21 days) but no more than 6 weeks (42 days) since last dose of chemotherapy, and within 4 weeks (28 days) since last tumour assessment.
boolean
C0008976 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
C1301880 (UMLS CUI [1,3])
C0392920 (UMLS CUI [2])
C0027651 (UMLS CUI [3,1])
C1516048 (UMLS CUI [3,2])
Exposure to Anti-EGFR Monoclonal Antibody | Exposure to Small Molecule Inhibitors | Small Molecule Inhibitors Against EGFR | gefitinib | erlotinib | C225
Item
prior exposure to monoclonal antibodies or small molecule inhibitors against egfr receptors. (e.g. gefitinib, erlotinib, c225)
boolean
C0332157 (UMLS CUI [1,1])
C4522190 (UMLS CUI [1,2])
C0332157 (UMLS CUI [2,1])
C1328819 (UMLS CUI [2,2])
C0243077 (UMLS CUI [2,3])
C1328819 (UMLS CUI [3,1])
C0243077 (UMLS CUI [3,2])
C0521124 (UMLS CUI [3,3])
C0034802 (UMLS CUI [3,4])
C1122962 (UMLS CUI [4])
C1135135 (UMLS CUI [5])
C0879636 (UMLS CUI [6])
CNS metastases Treated | Compression of spinal cord Treated | Stable status Clinical | Steroid therapy Discontinued
Item
patients with previously diagnosed and treated cns metastases or spinal cord compression may be considered if they are clinically stable and have been discontinued from steroid therapy for at least 4 weeks prior to first dose of study medication.
boolean
C0686377 (UMLS CUI [1,1])
C1522326 (UMLS CUI [1,2])
C0037926 (UMLS CUI [2,1])
C1522326 (UMLS CUI [2,2])
C0205360 (UMLS CUI [3,1])
C0205210 (UMLS CUI [3,2])
C0149783 (UMLS CUI [4,1])
C1444662 (UMLS CUI [4,2])
Lung Diseases, Interstitial
Item
any evidence of clinically active interstitial lung disease (patients with chronic, stable, radiographic changes who are asymptomatic need not be excluded)
boolean
C0206062 (UMLS CUI [1])
Biological Markers Status Known | Neoplasm EGFR Gene copy number | Neoplasm EGFR Gene Mutation Status | Neoplasm EGFR Protein expression
Item
known biomarker status of one or more of the following: tumour egfr gene copy number, tumour egfr gene mutation status, tumour egfr protein expression.
boolean
C0005516 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
C0205309 (UMLS CUI [1,3])
C0027651 (UMLS CUI [2,1])
C0034802 (UMLS CUI [2,2])
C0178655 (UMLS CUI [2,3])
C0027651 (UMLS CUI [3,1])
C0034802 (UMLS CUI [3,2])
C0596611 (UMLS CUI [3,3])
C0449438 (UMLS CUI [3,4])
C0027651 (UMLS CUI [4,1])
C0034802 (UMLS CUI [4,2])
C1171362 (UMLS CUI [4,3])